UNSPSC 51332513: Pipamperone

This classification denotes an anxiolytic with the molecular formula C21H30FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5402501F0W, chemically known as 1-(3-(p-fluorobenzoyl)propyl)-(1,4-bipiperidine)-4-carboxamide but generally known as pipamperone, which bears US NIH Compound Identifier 4830. European Medicines Agency schedules Pipamperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09860MIG.

UNSPSC 51332513 Pipamperone is a Commodity code that nominally covers a specific antipsychotic pharmaceutical, but recent state and local solicitations tagged to this code show little activity directly aligned with pipamperone procurement. The opportunities posted under this code instead reflect broader pharmaceutical supply and drug-management initiatives, including naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical contracting. State and local health departments, county health systems, and multistate cooperative purchasing alliances drive the buying activity visible under this code, though the actual scope spans harm-reduction supplies, prescription fulfillment infrastructure, and OTC product supply rather than pipamperone specifically.

Recent opportunities include Seminole County, Florida's IFB (posted June 30, 2026, due July 26, 2023) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the county health building; the Texas Health and Human Services Commission's RFI (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, effective July 1, 2026. The geographic spread reflects activity in Florida, Texas, and Minnesota with multistate cooperative participation. The code shows a mismatch between its nominal focus on a single antipsychotic compound and the actual procurement activity it carries — substance-abuse mitigation, prescription logistics, and commodity pharmaceutical supply dominate recent postings rather than pipamperone-specific demand.